[Skip to Content]
[Skip to Content Landing]
Observation
October 2017

Association of Ibrutinib Treatment With Bleeding Complications in Cutaneous Surgery

Author Affiliations
  • 1Weill Cornell Medical College, New York, New York
  • 2Department of Dermatology, Weill Cornell/New York Presbyterian, New York, New York
  • 3Dermatology Division, Memorial Sloan Kettering Cancer Center, New York, New York
  • 4Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell/New York Presbyterian, New York, New York
JAMA Dermatol. 2017;153(10):1069-1070. doi:10.1001/jamadermatol.2017.1877

Ibrutinib (IMBRUVICA, Pharmacyclics LLC) is a first-in-class Bruton tyrosine kinase (BTK) inhibitor that is indicated in a range of hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, and mantle cell lymphoma.1 Though ibrutinib is generally well tolerated, clinically significant bleeding events have been reported with the use of this medication.2 Knowledge of the potential bleeding complications is essential when treating patients who are taking ibrutinib and undergoing cutaneous surgery, especially on the face, to avoid adverse patient outcomes.

×